share_log

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

分析师意见:17位专家眼中的爱德华生命科学
Benzinga ·  2024/11/27 10:01
Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
17位分析师提供的分析师对爱德华兹生命科学(纽约证券交易所代码:EW)在上个季度的评级从看涨到看跌不等。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表简要概述了分析师最近的评级,提供了对过去30天情绪变化的见解,并与前几个月进行了比较以获得整体视角。
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $73.71, a high estimate of $90.00, and a low estimate of $63.00. This current average represents a 7.72% decrease from the previous average price target of $79.88.
分析师已经为爱德华兹生命科学设定了12个月的目标股价,显示平均目标股价为73.71美元,最高估计为90.00美元,低估值为63.00美元。目前的平均价格比之前的平均目标价79.88美元下降了7.72%。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级:深入概述
An in-depth analysis...
对分析师...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发